TEMPLATE DESIGN © 2008 www.PosterPresentations.com Background ResultsDiscussion and Conclusion References 1. Glass burn, J., L. Brady,P. Grigsby, Endometrium,

Slides:



Advertisements
Similar presentations
Breast cancer chemoprevention in the high-risk patient
Advertisements

OPTIONAL LOGO HERE Prevalence of endometrial cancer in symptamatic women with thickened endometrium Dr Maheswari SRINIVASAN MRCOG SpR, Mrs Shagaf BAKOUR.
Diagnostic Techniques for Endometrial Cancer By:Sara Lotfiyan.
Gynaecological Cancers
A significant increase in the incidence of endometrial cancer. This increased incidence of endometrial cancer has been widely interpreted to be a result.
Endometrial Cancer Screening for Cancer in Women.
Asymptomatic Endometrial Thickening in Postmenopausal Patient Dr
POST MENOPAUSAL WOMAN RAGINI REDDY CONSULTANT GYNAECOLOGIST.
Post Menopausal Bleeding
Breast Imaging Made Brief and Simple
Reproductive health. Cancer Definition Cancer Definition The abnormal growth of cells without normal control of body. Types of Cancer  Malignant Cancer.
Background The 2 week wait referral system was designed to expedite the referral of patients, suspected to have cancer, from Primary to Secondary care.
Ovarian cysts in Primary Care. When to refer? Physiological/pathological Benign/malignant Surgical approach? Open or keyhole? Do I need to do anything?
 The term post menopause is applied to women who have not experienced a menstrual bleed for a minimum of 12 months, assuming that they do still have.
Epidemiology of Breast Cancer Selected Highlights Jack Cuzick, Ph.D Cancer Research UK London.
Post-menopausal bleeding PV Dr Nasira Sabiha Dawood.
Risk factors and Epidemiology of Endometrial and Ovarian Cancer By: Tammy, Merissa, and Heather For: Nursing 519 Unit 6.
Breast Cancer. What is this Disease? Second leading cause of cancer death in women Malignant (cancerous) tumor –Develops from cells in the breast that.
The Obstetric Implications of Diabetes & Diabesity in Malaysia G MUNISWARAN OBSTETRICIAN & GYNAECOLOGIST HOSPITAL RAJA PERMAISURI BAINUN, IPOH.
Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.
By: Maureen Jaminal BIOL 316
Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP
TEMPLATE DESIGN © A Cost-effectiveness Analysis of Screening and Advocating Empiric Therapy for Asymptomatic Bacteriuria.
TEMPLATE DESIGN © Umbilical artery Pulsatility Index and different reference ranges: Does it really matter? Lo W., Mustafa.
TEMPLATE DESIGN © Objectives Methods This was a retrospective cohort data analysis of all women who presented with menorrhagia.
TEMPLATE DESIGN © Uterine sarcomas in RIPAS Hospital, Brunei; a 10 year retrospective study. Dr Alice Kurien, Dr Saw Ohnmar,
Breast Cancer Prevention Art or Science? Kristi McIntyre M.D. Texas Oncology 2005.
BREAST CANCER: Half a million women later… Amy Miglani M.D September 3, 2004.
Ovarian and Endometrial Cancer Using risk factors to help triage Adam Rosenthal PhD MRCOG Consultant Gynaecologist and Gynaecological Oncologist.
Colonic cancer screening in high risk groups
Tamoxifen associated changes
Malignant & Pre-malignant Diseases of the Endometrium Jose B Moran MD Assistant Professor III Section of Gynecologic Oncology Department of Obstetrics.
Post-menopausal bleeding Definition –Any vaginal bleeding after a period of amenorrhoea of 6 months or more in the perimenopausal age group –Menstruation.
Objectives: Our aim was to find the sensitivity of transvaginal ultrasonography (TVUS) in diagnosing women with gestational trophoblastic disease (GTD).
Appendix 2 Comparison of screening from age 20 and age 25 Table of harms and benefits.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
SCREENING IN GYNECOLOGICAL CANCER Taravat Fakheri OB/GYN KUMS.
Biostatistics Board Review Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016.
Radiological-histological size correlation in triple-negative breast cancer (TNBC) Abstract # 8254 C Thibault 1, M Gosset 2, F Chamming’s 3, M-A Lefrere-Belda.
Early Diagnosis of Gynaecological Cancer Rob Gornall Consultant Gynaecology GHNHST.
Dr. Ahmed jasim Ass.Prof.MBChB-DOG-FICMS COSULTANT OF GYN. & OBST. COSULTANT OF GYN. & OBST.
Date of download: 6/27/2016 From: Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer Ann Intern Med.
Lecture Fifteen Biomedical Engineering for Global Health.
M.D. Browning, M.D. ‘77.  Most Common Cancer of Female Reproductive System  60,000/year with 10,000 deaths  Normal Cells in the Endometrium.
Endometrial biopsy in subfertile women undergoing intrauterine insemination (IUI) cycles improves pregnancy rates Tumanyan A, Tchzmachyan R, Grigoryan.
  Andrea KAELIN AGTEN1 Giuseppe CALI2 Ana MONTEAGUDO1,3 Johana OVIEDO1
Women and Cardiovascular Disease
Statin use and risk of endometrial cancer:
Helle Kirkegaard1, Kresten R. Petersen1, Ole Mogensen2
COMPARISON OF RISK OF MALIGNANCY INDICES AND ASSESSMENT OF DIFFERENT NEOPLASIAS IN THE ADNEXA (ADNEX) MODEL AS PREOPERATIVE MALİGNANCY EVALUATION METHODS.
Operative Approach and
Endometrial hyperplasia
Post Menopausal Bleeding
Y W Liao1, S Shaman1, C S Chean1, S S Poon1, A Soltan1
ENDOMETRIAL HYPERPLASIA
Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies  Collaborative Group on Epidemiological.
Brady A. F. 1, Taylor A2, Lachlan K. L. 3 1
The postmenopausal bleeding (PMB)
930P - A retrospective single institution study evaluating clinical outcome and prognostic markers for endometrial and ovarian carcinosarcomas (CS) U.Asghar1,
UOG Journal Club: September 2011
Presenter: Wen-Ching Lan
An Audit on Complex hyperplasia reporting at Derriford Hospital
Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies  Collaborative Group on Epidemiological.
Volume 16, Issue 9, Pages (September 2015)
Volume 13, Issue 11, Pages (November 2012)
Volume 12, Issue 1, Pages (January 2011)
Management of Endometrial Hyperplasia D Hind Showman
Menopause. Menopause Health screening of healthy postmenopausal women.
Volume 13, Issue 9, Pages (September 2012)
UOG Journal Club: July 2019 Diagnostic accuracy of saline contrast sonohysterography in detecting endometrial polyps in women with postmenopausal bleeding:
Presentation transcript:

TEMPLATE DESIGN © Background ResultsDiscussion and Conclusion References 1. Glass burn, J., L. Brady,P. Grigsby, Endometrium, in Principles and Practice in Radiation Oncology. 2nd ed, ed. P.a. Brady. 1997: Lippincott-Raven Smith-Bindman, R., E. Weiss, and V. Feldstein, Ultrasound in Obstetrics and Gynaecology (5): p M. Gambacciani et al, Clinical usefulness of endometrial screening by ultrasound in asymptomatic postmenopausal women,Maturitas 48 (2004) 421–424, 4. Pe´rez-Medina T, Bajo J, Huertas MA, Rubio A. Predicting atypia inside endometrial polyps. J Ultrasound Med :125– 8. 5 DeWaay DJ, Syrop CH, Nygaard IE, DavisWA, Van Voorhis BJ. Natural history of uterine polyps and leiomyomata. Obstet Gynecol2002;100:3-7 6.Goldstein SR, Monteagudo A, Popiolek D,Mayberry P, Timor-Tritsch I. Evaluation of endometrial polyps. Am J Obstet Gynecol 2002;186: Orovieto R, Bar-Hava I, Dicker D, Bar J,Ben-Rafael Z, Neri A. Endometrial polyps during menopause: characterization and significance.Acta Obstet Gynecol Scand 1999;78; Ben-Arie A, Goldchmit C, Laviv Y, et al. The malignant potential of endometrial polyps. Eur J Obstet Gynecol 2004;115: Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort, Ian Jacobs, Aleksandra Gentry-Maharaj,et al The Lancet Oncology 1 January 2011 (Volume 12 Issue 1 Pages DOI: /S (10) ) Discussion : To diagnose 2 focal atypical hyperplasia, we performed 114 interventions in our study. We had no cases of endometrial cancer. The 2011 UKCTOCS[4] report shows the EC risk to be 5.9% among asymptomatic postmenopausal women found incidentally to have ET of ≥10 mm. This finding concurs with the earlier Smith Bindman(2004) statistical hypothesis that EC risk would be 6.7 % at an ET of ≥10 mm in asymptomatic postmenopausal women. The numbers needed to treat (NNT) would be 47.7 asymptomatic postmenopausal women for an ET of ≥5 mm,whereas it would be 17 women when the ET cut off ≥10 mm is used to trigger interventions. Moreover there are no studies to support improved mortality from EC due to earlier interventions in asymptomatic postmenopausal women. Conclusion : ET of ≥ 10 mm may be used as a cut off value to trigger invasive investigations in asymptomatic postmenopausal women. The screening burden can be further reduced by limiting interventions to women at increased risk of endometrial cancer. Methods and Results 128 histology samples were analysed 70 endometrial and 58 polyp samples. These numbers do not match with the number of interventions since in some both endometrial and polyp samples were obtained at one intervention. Among the two women with focal atypical, one woman had a personal history of breast cancer and use od aramidex. The other had a family history of breast cancer. Both women have used hormone replacement therapy for less than 2 years. 2) Asymptomatic postmenopausal women both with and without HRT/Tamoxifen use were included Main outcome measure : Diagnosis of endometrial cancer or complex atypical hyperplasia among these women. Results Demographics of our study cohort are shown below. Data was not available for all on risk factors for endometrial cancer such as age at menarche, body mass index, diabetes, hypertension, oral contraceptive use, hormone replacement use and breast cancer. The Median ET was 11, mean 11.2, and the range, mm. 26 women were managed conservatively.114 invasive interventions were performed and the outcomes are demonstrated below. Expectant Management of incidental thickened endometrium, is it negligence? Nirmala Murthy, Registrar, Obstetrics and Gynaecology, Liverpool Women’s Hospital, Laura Moncreiffe, Foundation Doctor, UHSM Mourad W Seif,Senior Lecturer and Consultant Gynaecologist, University of Manchester /St Mary’s Hospital, Manchester United Kingdom (UK) Exclusion criteria:313 women were excluded due to missing data, ET<10mm and those with PMB. Range Median Age at presentation (Yrs) Parity0-72 Age at menopause (Yrs) Endometrial cancer (EC) presents early as postmenopausal bleeding[1].Incidental findings of thickened endometrium and endometrial polyp are increasing due to extensive use of imaging across all specialties. Current UK practice is to offer investigations to both symptomatic and asymptomatic postmenopausal women when the endometrial thickness is 4 mm or more and or endometrial polyp. The cost effectiveness and clinical benefit of such investigations are uncertain[2] Smith Bindman[3] calculated the statistical probability of EC to be 6.7 % for an endometrial thickness (ET) of ≥10 mm in asymptomatic postmenopausal women. This is similar to the 7.2% risk of EC for an ET of ≥5 mm among women with postmenopausal bleeding. Similarly the risk of EC in polyps reportedly ranges from 0-4%[4-9]. However these studies included both symptomatic and asymptomatic postmenopausal women. Objective To identify the endometrial thickness cut off level for invasive interventions in asymptomatic postmenopausal women. Methods Design: Retrospective clinical audit. Study limitations include the retrospective nature, small sample size and single centre experience. 453 healthy postmenopausal UKCTOCS volunteers were referred with endometrial abnormalities to St. Mary’s Hospital, Manchester, Inclusion criteria: 1)140 asymptomatic healthy postmenopausal women with incidental ET ≥10 mm, endometrial polyp and or abnormal endometrium were included.